Tenuiss.com（Cincinnati, OH）

Tenuiss operates as a telehealth-focused weight loss and metabolic health clinic serving patients in South Carolina, with administrative operations based in Cincinnati, Ohio. The clinic specializes in peptide-based weight management protocols, specifically utilizing semaglutide, tirzepatide, and sermorelin to address obesity, metabolic dysfunction, and cardiovascular disease risk factors. Unlike traditional weight loss programs that rely solely on caloric restriction, Tenuiss structures treatment around GLP-1 receptor agonists and growth hormone-releasing peptides that work through distinct physiological mechanisms—semaglutide and tirzepatide by enhancing insulin secretion and reducing appetite through incretin mimicry, and sermorelin by stimulating natural growth hormone production to support lean muscle preservation during weight reduction. All peptide medications are sourced through state-licensed compounding pharmacies that adhere to USP 795 and 797 standards, ensuring pharmaceutical-grade quality for subcutaneous injection protocols.

The clinic’s treatment model centers on virtual consultations that allow South Carolina residents to access peptide therapy without geographic barriers to specialized metabolic care. During initial telehealth evaluations, providers assess patient history including cardiovascular risk markers such as hypertension, dyslipidemia, and insulin resistance, then design peptide regimens tailored to individual metabolic profiles and weight loss objectives. Semaglutide protocols typically begin at 0.25 mg weekly with gradual titration to therapeutic doses, while tirzepatide—a dual GIP/GLP-1 receptor agonist—offers an alternative pathway for patients requiring more robust appetite regulation or those with concurrent type 2 diabetes. Sermorelin is incorporated for patients over 40 or those experiencing age-related metabolic decline, administered as a subcutaneous injection that stimulates pituitary function rather than replacing growth hormone directly. This combination approach addresses both immediate weight reduction and long-term metabolic optimization.

Patients beginning treatment with Tenuiss receive detailed injection training via telehealth, including proper subcutaneous technique, injection site rotation protocols, and refrigeration requirements for peptide stability. The clinic provides ongoing monitoring through virtual check-ins where providers adjust dosing based on weight loss velocity, side effect profiles, and patient-reported outcomes related to appetite suppression, energy levels, and gastrointestinal tolerance. Common management strategies include addressing nausea through dose modulation, ensuring adequate protein intake to preserve lean mass during caloric deficit, and coordinating care with patients’ primary cardiologists when cardiovascular disease is present. The telehealth structure allows for responsive dose adjustments and side effect management without requiring in-person visits, which proves particularly valuable during the titration phase when gastrointestinal effects are most pronounced.

With a 5.0-star rating across 56 Google reviews, patient feedback consistently references successful weight loss outcomes, effective appetite control, and improved confidence as body composition changes occur. Reviewers frequently mention the clinic’s responsiveness to questions about injection technique, side effect management, and protocol adjustments, indicating an accessible support structure throughout treatment. Patients report achieving their weight goals through the structured peptide programs, with many noting improvements in overall well-being beyond the scale—including better energy regulation, reduced food preoccupation, and enhanced cardiovascular markers. The review patterns suggest that Tenuiss maintains active communication channels for troubleshooting injection-related concerns and optimizing peptide dosing as patients progress through their weight loss phases.

Tenuiss differentiates itself through exclusive telehealth delivery in South Carolina, eliminating the need for patients to locate local providers experienced in peptide-based weight management. The clinic’s focus on cardiovascular disease as a core specialization means treatment protocols account for the intersection of obesity and heart health, with peptide selection informed by each patient’s specific cardiac risk profile. By partnering with state-licensed compounding pharmacies rather than relying on commercial pharmaceutical supply chains, Tenuiss maintains consistent medication access even during periods of national shortages that have affected brand-name GLP-1 products. This operational model combines the clinical sophistication of peptide therapy with the convenience of virtual care, making evidence-based metabolic treatment accessible to South Carolina residents managing weight loss in the context of cardiovascular disease prevention or existing cardiac conditions.